

Anti-Nectin-4 Antibody (Enfortumab)

Introduction

Enfortumab is an antibody-drug conjugate (ADC) whose main component is enfortumab vedotin. It consists of the antibody enfortumab and the cytotoxic drug monomethyl auristatin E (MMAE). Enfortumab selectively delivers MMAE to cancer cells by targeting the Nectin-4 protein, thereby inhibiting the formation of microtubules, leading to cell cycle arrest and cell death. Enfortumab is mainly used to treat locally advanced or metastatic urothelial carcinoma

Product parameters

Alternative Names	Enfortumab vedotin, Enfortumab vedotin-ejfv
Target Accession	-
Target	Nectin-4
CAS number	1448664-46-7
Molecular Weight	145.44 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

■ Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

